Tag
Medicare Advantage beneficiaries with cancer receive guideline-concordant treatment similarly to Traditional Medicare enrollees but at lower costs and comparable timeliness, highlighting implications for healthcare policy and cost-effective
A cohort study demonstrates that reduced-dose 60-Gy chemoradiotherapy effectively maintains locoregional control in HPV-positive oropharyngeal cancer patients while minimizing treatment toxicity, with 5-year survival rates exceeding 92%.
RNA cancer vaccines are emerging as powerful tools against hard-to-treat cancers, with breakthroughs in melanoma, pancreatic, and brain cancers showing promise for widespread clinical adoption by 2029.
Over the past two decades, advances in therapy have doubled the median survival of multiple myeloma patients, transforming this once devastating cancer into a more manageable disease through targeted drugs and immune therapies.
A comprehensive analysis reveals that radiotherapy, chemotherapy, and genetic factors substantially contribute to subsequent neoplasms in long-term childhood cancer survivors, while lifestyle factors play a minimal role.
AI-powered protein design offers a fast, personalized approach to cancer treatment, enhancing immune response and minimizing side effects.
